Erlotinib, dasatinib, erlotinib-dasatinib versus placebo: A randomized, double-blind window study in operable head and neck squamous cell carcinoma (HNSCC).

Julie E. Bauman, Jennifer R. Grandis, William E. Gooding et al.|Journal of Clinical Oncology|2014

Cited by 5